Format

Send to

Choose Destination
Diabetes Care. 2013 Nov;36(11):3418-24. doi: 10.2337/dc12-2251. Epub 2013 Jul 17.

Cellular and humoral immune responses in type 1 diabetic patients participating in a phase III GAD-alum intervention trial.

Author information

1
Corresponding author: Mikael Chéramy, mikael.cheramy@liu.se.

Abstract

OBJECTIVE:

GAD formulated in aluminum hydroxide (GAD-alum) has previously been shown to induce preservation of residual insulin secretion in recent-onset type 1 diabetes, but recent phase II and III GAD-alum trials failed to reach primary outcomes. The European phase III study was therefore closed after 15 months, and only a minority of patients completed the 30 months of follow-up.

RESEARCH DESIGN AND METHODS:

This study aimed to characterize cellular and humoral responses in the Swedish patients (n = 148) participating in the phase III trial, receiving four (4D) or two (2D) GAD-alum doses or placebo. Serum GAD65 antibody (GADA) levels, GADA IgG1-4 subclass distribution, cytokine secretion, and proliferative responses in peripheral blood mononuclear cells (PBMCs) were analyzed.

RESULTS:

The GAD65-induced cytokine profile tended to switch toward a predominant Th2-associated profile over time both in the 2D and 4D group. The groups also displayed increased GADA levels and PBMC proliferation compared with placebo, whereas GADA IgG subclass distribution changed in 4D patients.

CONCLUSIONS:

Both 2D and 4D patients displayed GAD65-specifc cellular and humoral effects after GAD-alum treatment, but at different time points and magnitudes. No specific immune markers could be associated with treatment efficacy.

PMID:
23863909
PMCID:
PMC3816912
DOI:
10.2337/dc12-2251
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center